Madrigal (MDGL) 10b5-1 insider sales show multimillion proceeds in July–Aug 2025
Rhea-AI Filing Summary
Madrigal Pharmaceuticals (MDGL) filed a Form 144 reporting a proposed sale of 43,263 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $15,120,418.50 and 22,289,014 shares outstanding. The filing states the shares were acquired and are to be sold on 08/12/2025 following an exercise of stock options, with payment in cash. The notice also lists multiple recent 10b5-1 insider sales by Rebecca Taub and Paul A. Friedman in July–August 2025, including large transactions on 07/16/2025. Several identifying fields for the filer/issuer in the provided form appear blank.
Positive
- Form 144 filed providing public disclosure of the proposed sale of 43,263 shares
- Broker identified as Morgan Stanley Smith Barney LLC, giving execution routing details
- Securities were acquired by exercise of stock options and payment was in cash on the stated date
Negative
- Multiple sizeable 10b5-1 insider sales in the past three months, including Rebecca Taub: 26,444 shares for $9,347,062.51 on 07/16/2025
- Multiple sizeable 10b5-1 insider sales in the past three months, including Paul A. Friedman: 26,176 shares for $9,252,542.95 on 07/16/2025
- Several filer/issuer identifying fields in the provided form appear blank, limiting immediate verification from this document alone
Insights
TL;DR: Multiple scheduled insider sales disclosed; Form 144 shows a proposed sale of 43,263 shares valued at $15.12M.
The filing documents a straightforward Form 144 notice for the proposed public sale of 43,263 common shares via Morgan Stanley Smith Barney with a stated market value of $15,120,418.50. The shares were acquired and are to be sold on 08/12/2025 via exercise of stock options and paid in cash. The form also enumerates several 10b5-1 plan sales by named insiders in July–August 2025, producing multi-million dollar gross proceeds. This is disclosure of insider liquidity rather than an operational update.
TL;DR: Disclosure includes multiple insider 10b5-1 sales and required certifications, though some filer/issuer fields are blank.
The notice includes the statutory signature and representation language and identifies the broker and transaction details. It documents acquisition by option exercise and lists recent 10b5-1 sales by Rebecca Taub and Paul A. Friedman with exact dates and proceeds. The form as provided omits certain filer/issuer identification entries, which should be complete for full transparency in public filings.